Antimicrobial activity application of chiral bisoxazoline copper complex

The chiral bisoxazoline copper complex was solved by preparing bis{2-[4(R-or S)-phenyl-4,5-dihydrogenation]-2-oxazoline}phenol copper complex in The problem of insufficient use in the field of antibacterial field has achieved effective inhibition of Staphylococcus aureus, epidermatophyte flocculates and microsporidium gypsum-like, demonstrating efficient antibacterial activity and simple preparation technology.

CN119033792APending Publication Date: 2024-11-29HEFEI UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411072607.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the prior art, there are few reports on the medical use of chiral bisoxazoline copper complexes, especially in the field of antibacterial use, lack of in-depth research.

Method used

Bis{2-[4(R- or S)-phenyl-4,5-dihydrogenation]-2-oxo-sulfurization Azolinyl}phenol copper complex was separated by high temperature reflux and column chromatography to obtain single crystals of two configurations, and its antibacterial activity was studied.

Benefits of technology

This complex showed a significant antibacterial inhibition rate on Staphylococcus aureus, epidermophyte flocculates and microsporidium gypsum-like. It has simple process, convenient operation, high yield, and good stability and antibacterial effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033792A_ABST
    Figure CN119033792A_ABST
Patent Text Reader

Abstract

The application of the bis {2-[4 (R < + >)-phenyl-4, 5-dihydro]-2-oxazolinyl} phenol copper crystal complex I and the bis {2-[4 (R < + >)-phenyl-4, 5-dihydro]-2-oxazolinyl} phenol copper complex II is as follows: the two crystal complexes I and II respectively have a very good inhibition effect on staphylococcus aureus, epidermophyton floccosum and microsporum gypsum. The antifungal inhibition rates of the compound on epidermophyton floccosum and microsporum gypsum are respectively 81.146 + / -0.309, 66.383 + / -2.264, 60.283 + / -0.925 and 68.349 + / -1.702; the antibacterial inhibition rate on staphylococcus aureus is respectively 81.672 + / -0.309; 79.127 + / -0.667, and chemical formula of 79.127 + / -0.667 is as follows: # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the antibacterial use of a metal organic coordination compound (complex), in particular to the antibacterial use of a nitrogen-containing oxazoline metal organic complex, more specifically to the antibacterial use of a chiral bis-oxazoline copper complex. Background Art

[0002] With the development of organic chemistry, the application of metal organic compounds in organic synthesis is becoming more and more extensive. It is one of the most active fields in organic chemistry and has been widely used in organic synthesis reactions. The emergence of asymmetric synthesis reactions catalyzed by chiral ligands and transition metal complexes in the late 1960s greatly accelerated the research on chiral drugs. In recent years, chiral bisoxazoline ligand-copper metal complexes have made certain progress in the field of antibacterial drug chemistry research. [1-2]

[0003] References:

[0004] 1.Synthesis and crystal structure of bis[(4S,5S)-4,5-dihydro-4,5-diphenyl-2-2-(2'-oxidophenyl-χ-O)oxazole-χN]copper(II)and its application in the asymmetric Baeyer-Villiger reaction, Peng, Y.; et al, Journal ofOrganometallic Chemistry(2001),619(2),204-208;

[0005] 2.Syntheses, Crystal Structures and Antimicrobial Activity of Copper(II)Complexes with the Ligand N,N'-Bis(4-bromosalicylidene)propane-1,2-diamine.Hao, Yu-Mei; Sun, Chang-Chun, Acta chimica Slovenica(2024),71(2),304-311|;

[0006] 3.Syntheses, Crystal Structures and Antimicrobial Activity of Copper(II)Complexes with the Ligand N,N'-Bis(4-bromosalicylidene)propane-1,2-diamine. Hao, Yu-Mei; Sun, Chang-Chun, Acta chimica Slovenica (2024), 71(2), 304-311. Summary of the invention

[0007] The present invention aims to provide a Cu-N metal organic complex for application in the medical field, and the technical problem to be solved is to select o-hydroxyoxazoline as a ligand and study the antibacterial use of the copper complex of chiral bisoxazoline.

[0008] The inventor applied for two Chinese invention patents related to this patent in 2013: the application numbers are 201310305287.4 and 201310474961.1 respectively; the invention names are: a method for synthesizing a chiral bis-oxazoline copper complex crystal; a chiral oxazoline copper complex and its synthesis method. However, there are very few reports on the medical use of the complex. At present, the applicant has re-synthesized the reported complex to study the anti-cancer activity of the complex and obtained two configurations of the complex single crystal. After re-testing, a preliminary study of the use was conducted and it was found that it has antibacterial activity.

[0009] The chiral bis-oxazoline copper complex referred to in the present invention is a complex prepared from o-hydroxybenzonitrile, D-phenylglycinol and copper acetate monohydrate and represented by the following chemical formula:

[0010]

[0011] Chemical name: bis{2-[4(R-(+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex, referred to as complex (I).

[0012] The synthesis method of the complex is as follows: add 0.9938g (4.98mmol) of copper acetate monohydrate, 50mL of chlorobenzene, 1.0551g (5.28mmol) of o-hydroxybenzonitrile, and 3.9240g of D-phenylglycinol into a 100mL two-necked bottle, reflux the mixture at high temperature for 72h, stop the reaction, elute with petroleum ether and dichloromethane, separate by column chromatography, and naturally volatilize the last component to obtain a single crystal of the complex. The synthesis reaction is as follows:

[0013]

[0014] The chiral copper complex of bisoxazoline referred to in the present invention is a complex prepared from o-hydroxybenzonitrile, L-phenylglycinol and copper acetate monohydrate and represented by the following chemical formula:

[0015]

[0016] The synthesis method of the complex is as follows: 1.7923 g of copper acetate monohydrate, 50 mL of chlorobenzene, 1.7966 g of o-hydroxybenzonitrile, and 3.97686 g of L-phenylglycinol are added to a 100 mL two-necked bottle, the mixture is refluxed at high temperature for 72 hours, the reaction is stopped, the mixture is washed with petroleum ether and dichloromethane, column chromatography is performed for separation, and the last component is naturally volatilized to obtain a single crystal of the complex;

[0017] The synthetic reaction is as follows:

[0018]

[0019] The synthetic method can obtain the target product in one step, and the process is simple and the operation is convenient.

[0020] The two crystal complexes I and II have good inhibitory effects on Staphylococcus aureus, Epidermophyton floccosum and Microsporum gypseum. The antifungal inhibition rates of Epidermophyton floccosum and Microsporum gypseum are 81.146±0.309, 66.383±2.264 and 60.283±0.925, 68.349±1.702 respectively; the antibacterial inhibition rates of Staphylococcus aureus are 81.672±0.309 and 79.127±0.667 respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 X-ray diffraction analysis of bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex.

[0022] Figure 2 X-diffraction analysis of bis{2-[4(S-(-)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex. In the preparation and characterization part, due to the re-measurement of the unit cell parameters of bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex α=90°; β=99.2350(10)°; γ=90° is basically the same as the unit cell parameters provided by the 2013 Chinese invention patent 201310305287.4: a=10.0458(7)A alpha=90deg.b=22.9702(4)A beta=99.848(2)deg.c=11.1154(8)A gamma=90deg. This indicates that the structure of this substance is exactly the same as that of the previously reported substance. DETAILED DESCRIPTION

[0023] 1. Preparation of bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex

[0024] In a 100mL two-necked bottle, add 0.9938g (25.7mmol) of copper acetate monohydrate, 50mL of chlorobenzene, 1.1709g of o-hydroxybenzonitrile, and 3.9240g of D-phenylglycinol. Reflux the mixture at high temperature for 72h, stop the reaction, elute with petroleum ether and dichloromethane, separate by column chromatography, and evaporate the last component naturally to obtain a single crystal of the complex. Yield: 70%, mp:>200℃, [a] 5 D =+274.4°(c=1.036,CH2Cl2), elemental analysis: tested value: C: 66.22%, H: 4.39%, N: 5.26%; calculated value: 66.72%, 4.48%, N, 5.19%; IR(KBr): 3439, 2919, 1618, 1543, 1472, 1447, 1392, 1342,1266, 1154, 1082, 937, 853, 760, 700; MS(ESI): m-1 / z(%): calcd for C30H24N2O4Cu: 539.0780; found: 540.0264.

[0025] The crystal data of the complex are as follows:

[0026] Empirical formula C30H24N2O4Cu

[0027] Molecular weight 540.05

[0028] Temperature 170.00K

[0029] wavelength

[0030] Crystal system, space group monoclinic, P1 21 1

[0031] Unit cell parameters α=90°.

[0032] β=99.2350(10)°.

[0033] γ=90°.

[0034] volume

[0035] Charge density 4, 1.437 Mg / m^3

[0036] Absorption correction parameter 0.904 mm^-1

[0037] The number of electrons in a unit cell is 1116

[0038] Crystal size 0.17x 0.17x 0.05mm

[0039] Theta angle range 3.900 to 54.956

[0040] HKL indicator collection range: -12<=h<=11, -27<=k<16, -13<=l<=13 Collected / independent diffraction data 25900 / 7237 [R(int)=0.0363]

[0041] Theta=30.5 data integrity 99.3%

[0042] Absorption Correction Methods Multi-slice Scanning

[0043] The maximum and minimum transmittance are 1.0000 and 0.37633

[0044] The method used for refinement is the matrix least squares method of F^2.

[0045] Data quantity / usage limit Item / Parameter Number 7329 / 1 / 667

[0046] Methods used for refinement 1,062

[0047] The consistency factor of the diffraction point is R1 = 0.0468, ωR2 = 0.1085

[0048] The matching factor of the observed diffraction is R1 = 0.0602, ωR2 = 0.1173

[0049] Absolute configuration parameter 0.013(5)

[0050] The maximum difference on the Fourier plot Great Peaks and Valleys Typical bond length data for crystals:

[0051]

[0052]

[0053]

[0054]

[0055]

[0056] Typical bond angle data of crystals:

[0057]

[0058]

[0059]

[0060]

[0061]

[0062]

[0063]

[0064] 2. Preparation of bis{2-[4(S-(-)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex

[0065] In a 100mL two-necked bottle, add 1.0478g of copper acetate monohydrate, 50mL of chlorobenzene, 1.1709g of o-hydroxybenzonitrile, and 4.0516g of L-phenylglycinol. Reflux the mixture at high temperature for 72h, stop the reaction, elute with petroleum ether and dichloromethane, separate by column chromatography, and evaporate the last component naturally to obtain a single crystal of the complex. The yield is 76%, mp:>200℃, [a] 5 D =-201.5°(c=0.034,CH2Cl2), elemental analysis: calculated value: C: 66.72%, H: 4.48%, N: 5.19%; found value: C: 66.61%, H: 4.43%, N: 5.27%; IR: 3439, 2919, 1618, 1543, 1472, 1447, 1392, 1344, 1266, 1239, 1154, 1082, 937, 853, 760, 664, 569, 537; MS (ESI): m-1 / z(%): calcd for C30H24N2O4Cu: 539.0780; found: 540.0186.

[0066] The crystal data of the complex are as follows:

[0067] Empirical formula C30H24 N2O4 Cu

[0068] Molecular weight 540.05

[0069] Temperature 170.00K

[0070] wavelength

[0071] Crystal system, space group monoclinic, P1 21 1

[0072] Unit cell parameters α=90°.

[0073] β=99.1460(10)°.

[0074] γ=90°.

[0075] volume

[0076] Charge density 4, 1.439 Mg / m^3

[0077] Absorption correction parameter 4.938 mm^-1

[0078] The number of electrons in a unit cell is 1116

[0079] Crystal size 0.17x 0.17x 0.05mm

[0080] Theta angle range 3.900 to 55.050

[0081] HKL indicator collection range: -12<=h<=11, -27<=k<16, -13<=l<=13

[0082] Collected / independent diffraction data 9233 / 1 / 668 [R(int)=0.0363]

[0083] Theta=30.5 data integrity 99.3%

[0084] Absorption Correction Methods Multi-slice Scanning

[0085] The maximum and minimum transmittance are 1.0000 and 0.37633

[0086] The method used for refinement is the matrix least squares method of F^2.

[0087] Data Amount / Usage Limit Number of / Number of parameters 7329 / 1 / 667

[0088] Method used for refinement 1.062

[0089] The consistency factor of the diffraction point is R1 = 0.0812, ωR2 = 0.1750

[0090] The matching factors of the observed diffraction are R1=0.1012,ωR2=0.1857 Absolute configuration parameter 0.057(9)

[0091] Difference Fourier plot Maximum peaks and valleys

[0092] Table 2 Typical bond length data of Crystal II:

[0093]

[0094]

[0095]

[0096]

[0097] Table 3 Typical bond angle data of crystals

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104] C(16A)-C(21A)-C(20A) 119.5(10) C(16A)-C(21A)-C(22A) 120.3(9) C(20A)-C(21A)-C(22A) 120.0(10) O(4A)-C(22A)-C(21A) 116.7(9) N(2A)-C(22A)-O(4A) 115.7(9) N(2A)-C(22A)-C(21A) 127.6(9) O(4A)-C(23A)-H(23C) 110.7 O(4A)-C(23A)-H(23D) 110.7 O(4A)-C(23A)-C(24A) 105.2(8) H(23C)-C(23A)-H(23D) 108.8 C(24A)-C(23A)-H(23C) 110.7 C(24A)-C(23A)-H(23D) 110.7 N(2A)-C(24A)-C(23A) 102.7(8) N(2A)-C(24A)-H(24A) 109.6 N(2A)-C(24A)-C(25A) 111.2(7) C(23A)-C(24A)-H(24A) 109.6 C(25A)-C(24A)-C(23A) 113.9(8) C(25A)-C(24A)-H(24A) 109.6 C(26A)-C(25A)-C(24A) 118.9(9) C(26A)-C(25A)-C(30A) 118.6(9) C(30A)-C(25A)-C(24A) 122.4(8) C(25A)-C(26A)-H(26A) 119.5 C(27A)-C(26A)-C(25A) 120.9(10) C(27A)-C(26A)-H(26A) 119.5 C(26A)-C(27A)-H(27A) 120.0 C(26A)-C(27A)-C(28A) 120.1(10) C(28A)-C(27A)-H(27A) 120.0 C(27A)-C(28A)-H(28A) 120.0 C(29A)-C(28A)-C(27A) 120.0(10) C(29A)-C(28A)-H(28A) 120.0 C(28A)-C(29A)-H(29A) 120.1 C(28A)-C(29A)-C(30A) 119.8(10) C(30A)-C(29A)-H(29A) 120.1 C(25A)-C(30A)-C(29A) 120.4(9) C(25A)-C(30A)-H(30A) 119.8 C(29A)-C(30A)-H(30A) 119.8

[0105] 3. Antibacterial Activity Application

[0106] The organic complex crystals I and II synthesized according to the structural design of the active natural product of the present invention were screened for antibacterial activity against Escherichia coli, Staphylococcus aureus, Salmonella enterica and Pseudomonas aeruginosa in this experiment. The results showed that at a concentration of 100 μM, crystals I and II had a good inhibitory effect on Staphylococcus aureus, Epidermophyton floccosum and Microsporum gypseum. The specific results of the antibacterial activity test of the chiral organic complex crystals I and II are shown in Tables 3 and 4 below:

[0107] Escherichia coli ATCC25922, Staphylococcus aureus subsp. aureus ATCC29213, Salmonella enterica subsp. enterica ATCC14028, and Pseudomonas aeruginosa ATCC27853 were purchased from China General Microbiological Culture Collection Center (CGMCC).

[0108] (1) Experimental methods

[0109] The samples to be tested were added to a 96-well culture plate, and bacterial solution was added to each well to a final concentration of 5×10 5 CFU / mL; culture at 37℃ for 24h, and measure the OD value at 625nm with an enzyme marker. The experiment also set up a culture medium blank control, a bacterial control, and a ceftazidime and penicillin G sodium positive drug control.

[0110] (2) Antimicrobial activity application

[0111] The anticancer activity test results of the organic complex crystal I are shown in Tables 4 and 5 below.

[0112] Experimental Results

[0113] Table 4 Inhibitory effects of samples on two fungi

[0114] Center Number sample Concentration (μM) Epidermophyton floccosum Microsporum gypseum Comparison Terbinafine Hydrochloride 3 101.246±1.233 99.652±0.785 AH180 I 100 81.146±0.309 60.283±0.925 AH181 II 100 66.383±2.264 68.349±1.702

[0115] Table 5 Inhibitory effect of samples on 1 strain of bacteria

[0116] Center Number sample Concentration (μM) Staphylococcus aureus Comparison Penicillin G Sodium 14 99.928±0.126 AH180 I 100 81.672±0.309 AH181 II 100 79.127±0.667 .

Claims

1. A use of a bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex I shown by the following chemical formula and unit cell parameters: the crystal I copper complex shows certain inhibitory activity in anticancer cell tests such as lung cancer A-549, liver cancer SMMC-7721, breast cancer MDA-MB-231 and colon cancer SW480, and the inhibition rates are 3.263±0.09, 5.767±0.013, 3.044±0.089 and 17.23±0.89 respectively; the crystal II is 6.405±0.091, 6.206±0.231, 1.355±0.075 and 4.835±0.287, and the chemical formula of the complex is as follows: Its unit cell parameters are as follows: monoclinic system, P1 21 1; its unit cell parameters: α=90°; β=99.2350(10)°; γ=90°.

2. A use of a bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex II represented by the following chemical formula and unit cell parameters: the crystal II copper complex shows certain inhibitory activity in anticancer cell tests such as lung cancer A-549, liver cancer SMMC-7721, breast cancer MDA-MB-231 and colon cancer SW480, and the anticancer inhibition rates are 6.405±0.091, 6.206±0.231, 1.355±0.075 and 4.835±0.287, respectively. The chemical formula of the complex is as follows: Its unit cell parameters are as follows: monoclinic system, P1 21 1, unit cell parameters: α=90°; β=99.1460(10)°; γ=90°.